SCHEMBL2979457

SCHEMBL2979457

CNS(=O)(=O)Cc1ccc(Nc2nccc(-c3ccccc3OC)n2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK9 P50750 18/20 0.60
AURKA O14965 1/20 0.60
MAP4K4 O95819 1/20 0.60
ABL1 P00519 1/20 0.60
LCK P06239 1/20 0.60
MET P08581 1/20 0.60
PDGFRB P09619 1/20 0.60
FGFR1 P11362 1/20 0.60
FLT1 P17948 1/20 0.60
KDR P35968 1/20 0.60
FLT3 P36888 1/20 0.60
MAPK8 P45983 1/20 0.60
MAPK9 P45984 1/20 0.60
GSK3A P49840 1/20 0.60
GSK3B P49841 1/20 0.60
CDK5 Q00535 1/20 0.60
ACVR1 Q04771 1/20 0.60
MST1R Q04912 1/20 0.60
TYRO3 Q06418 1/20 0.60
NTRK2 Q16620 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3005881 0.91 CDK9 (0.68) CDK9AURKAMAP4K4ABL1LCK
SCHEMBL2985710 0.88 CDK9 (0.61) CDK9AURKAMAP4K4ABL1LCK
SCHEMBL14874685 0.82 CDK9 (0.68) CDK9AURKAMAP4K4ABL1LCK
SCHEMBL3758459 0.82 IKBKB (0.62) ABL1MAPK8GSK3B
SCHEMBL2995165 0.81 CDK9 (0.66) CDK9AURKAMAP4K4ABL1LCK
SCHEMBL3005997 0.79 CDK9 (0.70) CDK9AURKAMAP4K4ABL1LCK
SCHEMBL3008795 0.79 CDK9 (0.63) CDK9AURKAMAP4K4ABL1LCK
SCHEMBL1633860 0.78 JAK2 (0.55) CDK9CCNT1CDK2PTK2
SCHEMBL3013163 0.78 CDK9 (0.67) CDK9AURKAMAP4K4ABL1LCK
SCHEMBL4107381 0.77 CDK9 (0.55) CDK9AURKAMAP4K4ABL1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150011576-A1 Inhibitors of Protein Kinases ASTRAZENECA AB (SE) 2015-01-08 US claimed
US-8841315-B2 Inhibitors of protein kinases ASTRAZENECA AB (SE) 2014-09-23 US claimed
US-20130331407-A1 INHIBITORS OF PROTEIN KINASES INGENIUM PHARMACEUTICALS GMBH (DE) 2013-12-12 US claimed
US-8507511-B2 Inhibitors of protein kinases INGENIUM PHARMACEUTICALS GMBH (DE) 2013-08-13 US claimed
EP-2137165-B1 INHIBITORS OF PROTEIN KINASES INGENIUM PHARMACEUTICALS GMBH (DE) 2013-04-24 EP claimed
US-20100168144-A1 INHIBITORS OF PROTEIN KINASES ASTRAZENECA AB (SE) 2010-07-01 US claimed
EP-2137165-A1 INHIBITORS OF PROTEIN KINASES Ingenium Pharmaceuticals GmbH (DE) 2009-12-30 EP claimed
WO-2008129071-A1 INHIBITORS OF PROTEIN KINASES INGENIUM PHARMACEUTICALS GMBH (DE) 2008-10-30 WO claimed
US-20150011576-A1 Inhibitors of Protein Kinases ASTRAZENECA AB (SE) 2015-01-08 US disclosed
US-20150011576-A1 Inhibitors of Protein Kinases ASTRAZENECA AB (SE) 2015-01-08 US disclosed
US-8841315-B2 Inhibitors of protein kinases ASTRAZENECA AB (SE) 2014-09-23 US disclosed
US-8841315-B2 Inhibitors of protein kinases ASTRAZENECA AB (SE) 2014-09-23 US disclosed
US-20130331407-A1 INHIBITORS OF PROTEIN KINASES INGENIUM PHARMACEUTICALS GMBH (DE) 2013-12-12 US disclosed
US-8507511-B2 Inhibitors of protein kinases INGENIUM PHARMACEUTICALS GMBH (DE) 2013-08-13 US disclosed
US-20100168144-A1 INHIBITORS OF PROTEIN KINASES ASTRAZENECA AB (SE) 2010-07-01 US disclosed
US-20100168144-A1 INHIBITORS OF PROTEIN KINASES ASTRAZENECA AB (SE) 2010-07-01 US disclosed
US-20100168144-A1 INHIBITORS OF PROTEIN KINASES ASTRAZENECA AB (SE) 2010-07-01 US disclosed
EP-2137165-A1 INHIBITORS OF PROTEIN KINASES Ingenium Pharmaceuticals GmbH (DE) 2009-12-30 EP disclosed
WO-2008129071-A1 INHIBITORS OF PROTEIN KINASES INGENIUM PHARMACEUTICALS GMBH (DE) 2008-10-30 WO disclosed
WO-2008129071-A1 INHIBITORS OF PROTEIN KINASES INGENIUM PHARMACEUTICALS GMBH (DE) 2008-10-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130331407-A1 INHIBITORS OF PROTEIN KINASES CDK1, CDK2, CDK5 CDK9 11/4885AURKA 261/4885MAP4K4 88/4885
US-20150011576-A1 Inhibitors of Protein Kinases CDK1, CDK2, CDK5 CDK9 11/4885AURKA 261/4885MAP4K4 88/4885
US-20100168144-A1 INHIBITORS OF PROTEIN KINASES CDK1, CDK2, CCNI CDK9 11/4885AURKA 222/4885MAP4K4 81/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.